Skip to main content

Day: January 13, 2026

Half-year report on the liquidity contract – Renault SA – H2 2025

Regulated Information January 13, 2026HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT Under the liquidity agreement entered into between Renault SA and BNP Paribas, the following resources appeared on the liquidity account on December 31, 2025:143,730 shares€ 21,061,685.In the second half of 2025, were carried out:7,239 purchase transactions for 1,585,881 shares and € 54,894,7569,555 sale transactions for 1,571,001 shares and €54,826,677.As a reminder: 1. In the previous half-year report, on June 30, 2025, the following resources appeared on the liquidity account:128,850 shares€ 21,129,764.2. In the first half of 2025, were carried out:9,654 purchase transactions for 2,019,314 shares and €93,437,616 12,415 sale transactions for 1,914,067 shares and €89,088,2223. As of the date of the signature of the liquidity...

Continue reading

National Fuel Schedules First Quarter Fiscal 2026 Earnings Conference Call

WILLIAMSVILLE, N.Y., Jan. 13, 2026 (GLOBE NEWSWIRE) — National Fuel Gas Company (NYSE: NFG) today announced it will release its first quarter fiscal 2026 earnings results on Wednesday, January 28, 2026 after market close. A conference call to discuss the results will be held on Thursday, January 29, 2026 beginning at 9:00 a.m. ET and will include prepared remarks from the executive team followed by a question and answer session. All participants must pre-register to join this conference using the Participant Registration link. A webcast link to the conference call will be provided under the Events Calendar on the NFG Investor Relations website at investor.nationalfuelgas.com. A replay will be available following the call through the end of the day, Thursday, February 5, 2026. To access the replay, dial 1-866-813-9403 and provide...

Continue reading

Results of additional issuance – RIKB 38 0215 – RIKS 29 0917

As stated in paragraph 6 in General Terms of Auction for Treasury bonds, the Government Debt Management offered the equivalent of 10% of the nominal value sold in the auction 9. January, at the price of accepted bids.Series RIKB 38 0215 RIKS 29 0917ISIN IS0000037265 IS0000037711Additional issuance (nominal) 1,171,000,000 224,500,000Settlement date 01/14/2026 01/14/2026Total outstanding (nominal) 61,648,000,000 95,903,798,496

Continue reading

Westland Insurance acquires PV&V Insurance Centre Ltd. / Meester Insurance Centre

Westland Insurance strengthens its Ontario footprint, adding greenhouse insurance expertise to its growing portfolio Surrey, BC/Territories of the Coast Salish (Kwantlen, Katzie, Semiahmoo, Tsawwassen First Nations), Jan. 13, 2026 (GLOBE NEWSWIRE) — Westland Insurance, one of Canada’s largest insurance brokerages, today announced that it acquired PV&V Insurance Centre Ltd. and Meester Insurance Centre (collectively “PV&V”) effective January 1, 2026. The acquisition of PV&V underscores Westland’s commitment to strengthening its Ontario presence and broadening access to tailored insurance solutions for individuals and businesses across the province. With operating locations in Burlington and Smithville, PV&V has been proudly serving communities across Southern Ontario and the Niagara region since the 1980’s, including...

Continue reading

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based therapies for primary mitochondrial and severe renal diseases HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia’s core platform...

Continue reading

Glo Fiber Launches 8 Gig Fiber Internet Service

Glo FiberThe Glo Fiber team on the move!EDINBURG, Va., Jan. 13, 2026 (GLOBE NEWSWIRE) — Glo Fiber, powered by Shenandoah Telecommunications Company (Shentel) (Nasdaq: SHEN), has launched symmetrical 8 Gig fiber internet service for residential customers across Virginia, West Virginia, Maryland, Pennsylvania, Delaware, and Ohio. More than 400,000 homes and businesses now have access to Glo Fiber’s 100% fiber optic network and the fastest broadband speeds available in these markets. “Integrating 8 Gig internet service into our multi-gig product portfolio ensures Glo Fiber continues to lead with the fastest and most reliable internet available in the community,” said Rick Mason, Shentel’s Senior Vice President of Engineering and Operations. “Glo Fiber is building the infrastructure not just for today, but also for the future....

Continue reading

Dimensional Fund Advisors Ltd. : Form 8.3 – RIO TINTO PLC – Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Dimensional Fund Advisors Ltd. in its capacity as investment advisor and on behalf its affiliates who are also investment advisors (”Dimensional”). Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Rio...

Continue reading

Golden Triangle Ventures Signals Turnaround Momentum as Final Cleanup Nears, Balance Sheet Strengthens, and Core Businesses Accelerate Toward 2026 Expansion

AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) — via IBN —Golden Triangle Ventures (OTC: GTVH), today issued a corporate update signaling a decisive shift into its next phase, as the Company closes in on the final remaining items related to legacy cleanup, strengthens its balance sheet, and accelerates momentum across its core operating businesses. Over the past several months, Golden Triangle Ventures has taken direct action to address legacy balance sheet and structural matters that previously constrained the Company. Management confirmed that millions of dollars in historical debt have been removed from the balance sheet, materially improving the Company’s financial position and reducing legacy overhang. As a result, only a small number of final cleanup items remain, and the Company is now nearing completion of this phase. The...

Continue reading

Stellantis Announces 2026 Corporate Calendar

Stellantis Announces 2026 Corporate Calendar  AMSTERDAM, January 13, 2026 – Stellantis N.V. announced today the following corporate calendar for 20261: February 26, 2026        Full Year 2025 Financial Results April 30, 2026               Q1 2026 Financial Results July 30, 2026                Q2 2026 Financial Results October 28, 2026         Q3 2026 Financial Results A webcast and conference call hosted by Stellantis are also planned for each of the above dates. Webcasts of the presentations, as well as the related materials, will be accessible under the Investors section of the Stellantis corporate website at www.stellantis.com. The Annual General Meeting for the approval of Stellantis’ 2025 financial statements is scheduled for April 14, 20262. The 2026 corporate calendar is available on the corporate website at www.stellantis.com. #...

Continue reading

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL’s post-transaction share capital Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone payments TEL AVIV and BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) — XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTLB.TA) today announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (NASDAQ:...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.